AIBF - ETF AI Analysis
Top Page
iShares Future AI Beneficiaries ETF (AIBF)
Rating:70Outperform
Price Target:―
Positive Factors
Strong Top Holdings Performance
Several of the largest positions, including major health care and consumer brands, have shown strong gains this year, helping support the ETF’s overall results.
Broad Sector Diversification
The fund spreads its investments across many sectors such as health care, consumer defensive, industrials, technology, and others, which can help reduce the impact if one area of the market struggles.
Moderate Expense Ratio
The ETF’s fee level is reasonable for a specialized theme fund, allowing investors to access a focused AI-beneficiaries strategy without very high ongoing costs.
Negative Factors
Heavy U.S. Concentration
Almost all of the fund’s assets are invested in U.S. companies, which means performance is highly tied to the U.S. market and offers little geographic diversification.
Mixed Year-to-Date Fund Performance
The ETF’s overall performance so far this year has been only slightly positive, suggesting that the strategy has not yet delivered strong gains despite some standout holdings.
Key Holding with Weak Recent Performance
One of the largest positions, a major retailer, has shown weak results this year, which can drag on the fund given its meaningful weight in the portfolio.
AIBF vs. SPDR S&P 500 ETF (SPY)
AUM224.65M
RegionNorth America
Expense Ratio0.40%
BetaN/A
IssueriShares
Inception DateSep 22, 2026
Dividend YieldN/A
Asset ClassEquity
Index TrackedMorningstar US Artificial Intelligence Beneficiaries Select Index - USD - Benchmark TR Gross
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume40,182
30 Day Avg. Volume31,190
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
29.12Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering100
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AIBF Summary
The iShares Future AI Beneficiaries ETF (AIBF) invests in U.S. companies that are expected to benefit from the growing use of artificial intelligence, not just those building AI tools. It follows the Morningstar US Artificial Intelligence Beneficiaries Select Index and holds businesses across health care, consumer goods, industry, and technology. Well-known names include Walmart and Costco. Someone might invest in this ETF to tap into long-term growth from AI while staying diversified across many sectors. A key risk is that it is heavily tied to the future success of AI, so its value can rise or fall sharply with changes in AI-related trends and market sentiment.
How much will it cost me?This ETF has an expense ratio of 0.40%, which means you’ll pay about $4 per year for every $1,000 you invest. That’s a bit higher than a typical broad-market index ETF because this is a specialized, actively designed thematic fund focused on companies expected to benefit from AI.
What would affect this ETF?This ETF could benefit if artificial intelligence adoption accelerates across U.S. health care, consumer, and industrial companies, helping major holdings like Walmart, Eli Lilly, and GE cut costs, boost productivity, and create new products and services. On the other hand, slower economic growth, tighter regulation of AI or health care, and higher interest rates that pressure growth-focused and technology-related stocks could weigh on the fund’s future performance.
AIBF Top 10 Holdings
This AI beneficiaries ETF leans heavily on steady U.S. blue chips rather than flashy pure-play tech. Health care names like AbbVie and Merck are doing much of the heavy lifting, with rising shares and solid pipelines helping power the fund. Palo Alto Networks is the clear high-flyer, riding the AI-driven cybersecurity wave and adding extra spark. On the flip side, Walmart and GE Aerospace have been lagging lately, acting as a bit of a drag. Overall, the fund is U.S.-centric and tilted toward defensive, AI-enabled giants rather than speculative upstarts.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Walmart | 4.11% | $9.33M | $883.42B | 9.34% | 78 Outperform | |
| AbbVie | 3.93% | $8.92M | $488.55B | 19.94% | 66 Neutral | |
| Costco | 3.92% | $8.91M | $419.61B | 1.82% | 72 Outperform | |
| Eli Lilly & Co | 3.74% | $8.49M | $1.11T | 41.48% | 72 Outperform | |
| Palo Alto Networks | 3.53% | $8.01M | $342.56B | 100.80% | 73 Outperform | |
| Johnson & Johnson | 3.46% | $7.87M | $630.04B | 37.08% | 78 Outperform | |
| Procter & Gamble | 3.15% | $7.15M | $351.26B | 1.03% | 69 Neutral | |
| Coca-Cola | 3.13% | $7.10M | $378.84B | 31.34% | 75 Outperform | |
| GE Aerospace | 2.87% | $6.52M | $319.78B | 5.73% | 72 Outperform | |
| Merck & Company | 2.85% | $6.48M | $359.22B | 69.32% | 80 Outperform |
AIBF Technical Analysis
Positive
―
Price Trends
Market Momentum
83.56
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For AIBF, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of 83.56 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AIBF.
AIBF Peer Comparison
Comparison Results
Performance Comparison
AIBF
iShares Future AI Beneficiaries ETF
25.39
0.32
1.28%
AIPO
Defiance AI & Power Infrastructure ETF
―
―
―
UFOX
Defiance Connective Technologies Etf
―
―
―
FEPI
REX FANG & Innovation Equity Premium Income ETF
―
―
―
AIPI
REX AI Equity Premium Income ETF
―
―
―
GPTY
YieldMax AI & Tech Portfolio Option Income ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents